[1] National Health and Family Planning Commission Expert Committee on Rational Drugs Use. Guidelines for rational drug use of coronary heart disease (2nd edition)[J]. Zhongguo Yi Xue Qian Yan Za Zhi (Dian Zi Ban), 2018, 10:1-130.[国家卫生计生委合理用药专家委员会. 冠心病合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2018, 10:1-130.]
[2] Cardiology of Chinese Medical Association, Chinese Society; Editorial Board of Chinese Journal of Cardiology. 2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction[J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2019, 47:766-783.[中华医学会心血管病学分会, 中华心血管病杂志编辑部委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47:766-783.]
[3] National Health and Family Planning Commission Expert Committee on Rational Drugs Use. Guidelines for rational use of thrombolytic therapy for acute ST segment elevation myocardial infarction (2nd edition)[J]. Zhongguo Yi Xue Qian Yan Za Zhi (Dian Zi Ban), 2019, 11:40-65.[国家卫生计生委合理用药专家委员会. 急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2019, 11:40-65.]
[4] Chinese Stroke Society, Neurointerventional Branch of Chinese Stroke Society, Interventional Group of Stroke Prevention and Control Committee of China Preventive Medicine Association. Chinese guidelines for endovascular treatment of acute ischemic stroke 2018[J]. Zhongguo Zu Zhong Za Zhi, 2018, 7:706-729.[中国卒中学会, 中国卒中学会神经介入分会, 中华预防医学会卒中预防与控制专业委员会介入学组. 急性缺血性卒中血管内治疗中国指南2018[J]. 中国卒中杂志, 2018, 7:706-729.]
[5] Liu LP, Chen WQ, Duan WY, Huo XC, Xu WH, Li SJ, Li ZX, Huang LA, Wang CX, Zheng HG, Wang YJ; Chinese Stroke Society Chinese Cerebrovascular Diseases Clinical Magagement Guidelines Writing Committee. Chinese cerebrovascular disease clinical management guidelines (excerpted version):clinical management of ischemic cerebrovascular disease[J]. Zhongguo Zu Zhong Za Zhi, 2019, 14:85-102.[刘丽萍, 陈玮琪, 段婉莹, 霍晓川, 徐蔚海, 李淑娟, 李子孝, 黄立安, 王春雪, 郑华光, 王拥军; 中国卒中学会中国脑血管病临床管理指南撰写委员会. 中国脑血管病临床管理指南(节选版)——缺血性脑血管病临床管理[J]. 中国卒中杂志, 2019, 14:85-102.]
[6] Yang M, Huo X, Gao F, Wang A, Ma N, Shi H, Chen W, Wang S, Wang Y, Miao Z. Low-dose rescue tirofiban in mechanical thrombectomy for acute cerebral large-artery occlusion[J]. Eur J Neurol, 2020.[Epub ahead of print]
[7] Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the early management of patients with acute ischemic stroke:2019 update to the 2018 guidelines for the early management of acute ischemic stroke. A guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2019, 50:e344-418.
[8] Chinese Stroke Society. Expert consensus on clinical application of tirofiban in atherosclerotic cerebrovascular disease[J]. Zhongguo Zu Zhong Za Zhi, 2019, 14:1034-1044.[中国卒中学会. 替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识[J]. 中国卒中杂志, 2019, 14:1034-1044.]
[9] Chen YD, Dong W. Registration study on the clinical application of tirofiban in acute coronary syndrome[C]//Compilation of papers of the 15th national conference of Chinese Medical Association on cardiovascular diseases, Tianjin, 2013. Beijing:Chinese Medical Association, Branch of Cardiology, 2013:114.[陈韵岱, 董蔚. 国产替罗非班在急性冠脉综合症中临床应用的注册研究[C]//. 中华医学会第十五次全国心血管病学术大会论文汇编, 天津, 2013. 北京:中华医学会心血管病学会, 2013:114.]
[10] Zhang Y, Zhang QQ, Fu C, Wang L, Zhang GQ, Cao PW, Chen GF, Fu XM. Clinical efficacy of tirofiban combined with a Slitaire stent in treating acute ischemic stroke[J]. Braz J Med Biol Res, 2019, 52:e8396.
[11] Wu C, Sun C, Wang L, Lian Y, Xie N, Huang S, Zhao W, Ren M, Wu D, Ding J, Song H, Wang Y, Ma Q, Ji X. Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis[J]. Stroke, 2019, 50:3481-3487.
[12] Liu J, Shi Q, Sun Y, He J, Yang B, Zhang C, Guo R. Efficacy of tirofiban administered at different time points after intravenous thrombolytic therapy with alteplase in patients with acute ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2019, 28:1126-1132.
[13] Mangiafico S, Cellerini M, Nencini P, Gensini G, Inzitari D. Intravenous glycoprotein Ⅱ b/Ⅲ a inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke[J]. AJNR Am J Neuroradiol, 2005, 26:2595-2601.
[14] Ihn YK, Sung JH, Kim BS. Intravenous glycoprotein Ⅱ b/Ⅲ a inhibitor (tirofiban) followed by low-dose intra-arterial urokinase and mechanical thrombolysis for the treatment of acute stroke[J]. Neuroradiol J, 2011, 24:907-913.
[15] Cheng Z, Geng X, Gao J, Hussain M, Moon SJ, Du H, Ding Y. Intravenous administration of standard dose tirofiban after mechanical arterial recanalization is safe and relatively effective in acute ischemic stroke[J]. Aging Dis, 2019, 10:1049-1057.
[16] Feng XW, Chen ZC, Zhong GL, Lou M. Safety of tirofiban in patients with acute cerebral infarct receiving endovascular therapy[J]. Zhejiang Da Xue Xue Bao (Yi Xue Ban), 2017, 46:397-404.[冯学问, 陈智才, 钟根龙, 楼敏. 急性缺血性卒中患者血管内治疗后应用替罗非班的安全性及预后分析[J]. 浙江大学学报(医学版), 2017, 46:397-404.]
[17] Expert Consensus Group on the Treatment of Symptomatic Intracranial Atherosclerotic Stenosis. Chinese expert consensus on the treatment of symptomatic intracranial atherosclerotic stenosis[J]. Zhonghua Nei Ke Za Zhi, 2013, 52:271-275.[症状性颅内动脉粥样硬化性狭窄血管内治疗专家共识组. 症状性颅内动脉粥样硬化性狭窄血管内治疗中国专家共识[J]. 中华内科杂志, 2013, 52:271-275.]
[18] Wang YB, Liu PJ. Application of tirofiban in carotid angioplasty stenting of the intracraIlial artery stenosis[J]. Xianning Xue Yuan Xue Bao (Yi Xue Ban), 2012, 26:388-391.[王育斌, 刘佩军. 替罗非班在颅内动脉狭窄支架置入术中的应用[J]. 咸宁学院学报(医学版), 2012, 26:388-391.]
[19] Brinjikji W, Morales-Valero SF, Murad MH, Cloft HJ, Kallmes DF. Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms:a Meta-analysis[J]. AJNR Am J Neuroradiol, 2015, 36:121-125.
[20] Limaye K, Zanaty M, Hudson J, Nakagawa D, Al Kasab S, Alvarez C, Dandapat S, Kung DK, Ortega-Gutierrez S, Jabbour P, Samaniego EA. The safety and efficacy of continuous tirofiban as a monoantiplatelet therapy in the management of ruptured aneurysms treated using stent-assisted coiling or flow diversion and requiring ventricular drainage[J]. Neurosurgery, 2019, 85:E1037-1042.
[21] Chinese Expert Consensus on the Use of Platelet Glycoprotein Ⅱ b/Ⅲ a Receptor Antagonists in the Treatment of Coronary Atherosclerotic Heart Disease (2016). Consensus on the use of platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonists in the treatment of coronary atherosclerotic heart disease (2016)[J]. Xin Fei Xue Guan Bing Za Zhi, 2016, 35:923-932.[血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在冠状动脉粥样硬化性心脏病治疗的中国专家共识(2016)专家组. 血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在冠状动脉粥样硬化性心脏病治疗的中国专家共识(2016)[J]. 心肺血管病杂志, 2016, 35:923-932.]
[22] Corrigendum to:2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J, 2019, 40:3096.
[23] Seitz RJ, Meisel S, Moll M, Wittsack HJ, Junghans U, Siebler M. The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions[J]. Neurology, 2004, 62:2110-2112.
[24] Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion[J]. Stroke, 2004, 35:705-709.
[25] Li W, Lin L, Zhang M, Wu Y, Liu C, Li X, Huang S, Liang C, Wang Y, Chen J, Feng W. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients[J]. Stroke, 2016, 47:2649-2651.
[26] Chalouhi N, Jabbour P, Kung D, Hasan D. Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms[J]. Neurosurgery, 2012, 71:710-714.
[27] Tian HA, Zao W, Yi GF. Application of intra:arterial infusion of tirofiban in dealing with acute thromboembolism occurred during embolization therapy for intracranial aneurysms:a preliminary study[J]. Jie Ru Fang She Xue Za Zhi, 2012, 21:718-721.[田红岸, 赵卫, 易根发. 动脉灌注替罗非班在处理颅内动脉瘤栓塞术中急性血栓栓塞的研究[J]. 介入放射学杂志, 2012, 21:718-721.]
[28] Feng L, Feng G, Chen J, Liu J, Su CM, Liu YZ. Tirofiban combined with urokinase in the treatment of acute thrombosis during coil embolization of ruptured aneurysms[J]. Zhonghua Shen Jing Yi Xue Za Zhi, 2013, 12:490-493.[冯雷, 冯光, 陈剑, 刘军, 苏春海, 刘运振. 替罗非班联合尿激酶治疗破裂动脉瘤弹簧圈栓塞过程中急性血栓形成[J]. 中华神经医学杂志, 2013, 12:490-493.]
[29] Tang S. Heal prophylactic application of tirofiban in ruptured intracranial a neurysm intervention[J]. Zhong Wai Yi Liao, 2016, 35:145-146.[唐爽. 替罗非班在颅内破裂动脉瘤介入治疗术中预防性应用研究[J]. 中外医疗, 2016, 35:145-146.]
[30] Ding MX, Liu JX, Xie B, Liu TZ, Han ZA. Application of tirofiban in acute thrombosis during embolization for intracranial aneurysms[J]. Zhongguo Wei Qin Xi Shen Jing Wai Ke Za Zhi, 2017, 22:101-104.[丁明祥, 刘俊秀, 谢兵, 刘天助, 韩志安. 替罗非班在颅内动脉瘤栓塞术中急性血栓形成的应用[J]. 中国微侵袭神经外科杂志, 2017, 22:101-104.]
[31] Jin EL, Zhu Y, Yang L, Chen G, Li HH, Zhao YY, Sheng LQ, Tang W, Yang M, Pan L, Li J. Clinical study on antiplatelet aggregation of tirofiban in stent assisted embolization of intracranial aneurysms[J]. Zhonghua Shen Jing Wai Ke Za Zhi, 2017, 33:349-353.[金二亮, 祝源, 杨李, 陈刚, 李欢欢, 赵曰圆, 盛柳青, 汤伟, 杨铭, 潘力, 李俊. 替罗非班在颅内动脉瘤支架辅助栓塞术中抗血小板聚集的临床研究[J]. 中华神经外科杂志, 2017, 33:349-353.]
[32] Mou RT, Liu YZ, Ni CF, Chen L, Li B. Safety and efficacy embolization of tirofiban in stent:assisted coil in intracranial aneurysms[J]. Zhongguo Jie Ru Ying Xiang Yu Zhi Liao Xue, 2017, 14:129-133.[牟汝涛, 刘一之, 倪才方, 陈珑, 李波. 替罗非班在支架辅助颅内动脉瘤栓塞中的安全性及有效性[J]. 中国介入影像与治疗学, 2017, 14:129-133.]
[33] Lu XY, Li QY, Chen B. Intra-arterial tirofiban thrombolysis for acute thromboembolism during stent-assisted coil embolization for ruptured intracranial aneurysms[J]. Guo Ji Shen Jing Bing Xue Shen Jing Wai Ke Xue Za Zhi, 2018, 45:22-24.[陆新宇, 李巧玉, 陈波. 替罗非班治疗支架辅助弹簧圈栓塞动脉瘤术中急性血栓形成[J]. 国际神经病学神经外科学杂志, 2018, 45:22-24.]